Kanter Stacy J. 4
4 · Applied Therapeutics, Inc. · Filed Feb 4, 2026
Research Summary
AI-generated summary of this filing
Applied Therapeutics (APLT) Director Stacy Kanter Sells Shares in Merger
What Happened
- Stacy J. Kanter, a director of Applied Therapeutics (APLT), reported dispositions totaling 328,690 shares on 2026-02-03. The shares were cancelled/converted pursuant to the company's merger agreement; the filing reports the transactions as dispositions to the issuer and in connection with a change of control.
- Under the Merger Agreement, each cancelled share converted into $0.088 in cash (net per share) plus one non‑tradeable contingent value right (CVR). The cash component for 328,690 shares is about $28,924.72; holders also receive the CVR per the agreement. Several of the reported dispositions relate to derivative awards (RSUs and options) that were deemed vested and converted or cancelled in the merger.
Key Details
- Transaction date(s): Reported dispositions dated 2026-02-03; Merger effective time per footnote: 2026-01-28.
- Price/consideration: $0.088 cash per common share plus one non-tradeable contingent value right (filing shows N/A for per-line price).
- Shares disposed: 22,500; 42,500; 20,460; 10,230; 16,500; 16,500; and 200,000 — total 328,690 shares.
- Derivative items: RSUs (vested and converted into merger consideration) and certain stock options were vested or cancelled per the Merger Agreement (out‑of‑the‑money options cancelled for no consideration).
- Shares owned after transaction: not specified in the filing.
- Filing date: Form 4 filed 2026-02-04. The filing does not state that it was late.
Context
- These dispositions were driven by a corporate merger/tender offer, not open‑market selling. Cancellation/conversion of common shares, RSUs and certain options into the merger consideration is common in change‑of‑control transactions and does not necessarily reflect personal trading intent.
- The cash received is modest (~$28.9K); holders also received CVRs, which may have future contingent value depending on the agreement terms.
Insider Transaction Report
Form 4Exit
Kanter Stacy J.
Director
Transactions
- Disposition to Issuer
Common Stock
[F1][F2]2026-02-03−22,500→ 42,500 total - Disposition from Tender
Common Stock
[F1][F3]2026-02-03−42,500→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
[F4]2026-02-03−20,460→ 0 totalExercise: $1.05→ Common Stock (20,460 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
[F4]2026-02-03−10,230→ 0 totalExercise: $1.05→ Common Stock (10,230 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
[F4]2026-02-03−16,500→ 0 totalExercise: $1.05→ Common Stock (16,500 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
[F4]2026-02-03−16,500→ 0 totalExercise: $1.05→ Common Stock (16,500 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
[F4]2026-02-03−200,000→ 0 totalExercise: $0.40→ Common Stock (200,000 underlying)
Footnotes (4)
- [F1]Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration").
- [F2]Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration.
- [F3]Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration.
- [F4]Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.
Signature
/s/ Leslie D. Funtleyder, as attorney-in-fact|2026-02-04